Skip to main content
. Author manuscript; available in PMC: 2011 Nov 4.
Published in final edited form as: Mol Cancer Ther. 2010 Aug 17;9(10):2785–2792. doi: 10.1158/1535-7163.MCT-10-0481

Figure 4.

Figure 4

Effects of the combination of TAK-701 and gefitinib on the growth of gefitinib-resistant NSCLC cells in vivo. Nude mice with tumor xenografts established by subcutaneous injection of HCC827-Mock (A) or HCC827-HGF2 (B) cells were treated for 7 weeks with vehicle (control), gefitinib (50 mg/kg), TAK-701 (5 mg/kg), or both drugs, as described in Materials and Methods. Tumor volume was determined at the indicated times after the onset of treatment. Data are means ± SEM from five mice per group.